Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana.
Journal article
Authors / Editors
No matching items found.
Research Areas
No matching items found.
Publication Details
Author list: Dryden-Peterson S, Jayeoba O, Hughes MD, Jibril H, Keapoletswe K, Tlale J, Modise TA, Asmelash A, Moyo S, van Widenfelt E, Makhema J, Essex M, Shapiro RL, Lockman S
Publisher: Lippincott, Williams & Wilkins
Publication year: 2011
Journal: Journal of Acquired Immune Deficiency Syndromes (1525-4135)
Journal acronym: J Acquir Immune Defic Syndr
Volume number: 58
Issue number: 3
Start page: 353
End page: 7
Number of pages: -345
ISSN: 1525-4135
eISSN: 1944-7884
Languages: English-Great Britain (EN-GB)
Abstract
Few studies have compared the programmatic effectiveness of the recommended strategies of antenatal highly active antiretroviral therapy (HAART) and zidovudine for prevention of mother-to-child transmission. We prospectively followed infants (93% formula fed) whose mothers who took either HAART (258 infants) or zidovudine (170 infants) during pregnancy in the Botswana national program. Overall, 10 infants (2.5%) acquired HIV--9 infants in the zidovudine group (5.5%, 95% confidence interval: 2.6% to 10.2%) and 1 infant in the HAART group (0.4%, 95% confidence interval: 0.0% to 2.2%). Maternal HAART was associated with decreased prevention of mother-to-child transmission (P = 0.001) and improved HIV-free survival (P = 0.040) compared with zidovudine (with or without single-dose nevirapine) in a programmatic setting.
Keywords
No matching items found.
Documents
No matching items found.
